ArticleDiabetes care2026
Long-term Effect of C-Peptide Level on Clinical Outcomes in the Scottish Type 1 Bioresource Cohort.
Article in Diabetes care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo characterize associations of C-peptide measurements with type 1 diabetes (T1D) complications across long-term clinical follow-up in a large representative population cohort (Scottish Diabetes Research Network Type 1 Bioresource [SDRNT1BIO]). RESEARCH DESIGN AND
methodsSDRNT1BIO includes people with a clinical diagnosis of T1D who are aged 16 years or older at enrollment. Their median diabetes duration is 21 (interquartile range 11-31) years. C-peptide was measured in an untimed blood sample using the Roche immunoassay with a lower limit of detection of 3 pmol/L. Incident events and continuous outcomes were captured through electronic health record linkage across follow-up. Associations were studied using Poisson generalized linear models and linear mixed models adjusted for sex, age, time-updated T1D duration, year of entry, and age/T1D duration interaction.
resultsParticipants (n = 5,630) were followed for a median of 10.8 years. Inverse associations were found between baseline C-peptide level and diabetic ketoacidosis (DKA) (P < 0.0001; no. of events = 1,015), severe hospitalized hypoglycemia (SHH) (P = 0.0055; n = 539), and incident retinopathy (P < 0.0001; n = 1,172). These associations persisted when adjusted for time-updated glycosylated hemoglobin. No associations were found between baseline C-peptide levels and cardiovascular disease (P = 0.9; n = 714) or death (P = 0.8; n = 566). In a subset of participants (n = 407) with serial C-peptide measures, follow-up C-peptide level was inversely associated with risk for DKA (P < 0.001; n = 92) and there was a borderline association with SHH (P = 0.015; n = 28).
conclusionsThese data demonstrate the importance of C-peptide level and its maintenance for glycemic control and avoidance of acute and chronic complications of T1D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.